We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
S100A8/A9 is the first predictive marker for neonatal sepsis.
- Authors
Pirr, Sabine; Dauter, Louise; Vogl, Thomas; Ulas, Thomas; Bohnhorst, Bettina; Roth, Johannes; Viemann, Dorothee
- Abstract
S100A8/A9 serum levels only slightly but not significantly increased at initial presentation of sepsis compared to control children due to the already high normal levels of S100A8/A9 in preterm control infants during the first 2 weeks of life (A). Neonatal sepsis is a leading cause of childhood mortality worldwide particularly affecting preterm infants, who are often exposed to empirical antibiotics since sepsis biomarkers lack sensitivity in this patient group and markers predicting the risk of sepsis have not been identified yet.1,2 In our study, serum S100A8/A9 proved as an independent predictive marker of late-onset neonatal sepsis (LOS) in preterm infants, which for the first time offers the opportunity to change current treatment policies by improving antibiotic stewardship and timely individualized therapeutic intervention.
- Subjects
NEONATAL sepsis; NEONATAL infections; NEWBORN infants; RETROLENTAL fibroplasia; PREMATURE infants
- Publication
Clinical & Translational Medicine, 2021, Vol 11, Issue 4, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.338